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Pituitary adenylate cyclase activating polypeptide (PACAP) has neuroprotective effects in different neuronal and retinal injuries.
Retinal ischemia can be effectively modelled by permanent bilateral common carotid artery occlusion (BCCAO), which causes
chronic hypoperfusion-induced degeneration in the entire rat retina. The retinoprotective effect of PACAP 1-38 and VIP is well-
established in ischemic retinopathy. However, little is known about the effects of related peptides and PACAP fragments in ischemic
retinopathy. The aim of the present study was to investigate the potential retinoprotective effects of different PACAP fragments
(PACAP 4-13, 4-22, 6-10, 6-15, 11-15, and 20-31) and related peptides (secretin, glucagon) in BCCAO-induced ischemic retinopathy.
Wistar rats (3-4 months old) were used in the experiment. After performing BCCAO, the right eyes of the animals were treated
with PACAP fragments or related peptides intravitreal (100 pM), while the left eyes were injected with saline serving as control eyes.
Sham-operated (without BCCAO) rats received the same treatment. Routine histology was performed 2 weeks after the surgery;
cells were counted and the thickness of retinal layers was compared. Our results revealed significant neuroprotection by PACAP
1-38 but did not reveal retinoprotective effect of the PACAP fragments or related peptides. These results suggest that PACAP 1-38
has the greatest efficacy in ischemic retinopathy.
1. Introduction
Pituitary adenylate cyclase activating polypeptide (PACAP) is
a neuropeptidewithwidespread occurrence in various organs
and diverse effects both in the nervous system and in the
periphery [1, 2]. PACAP is strongly expressed in the central
nervous system, where it exerts several effects such that it is a
central regulator of circadian rhythmic activities [3], plays a
role in memory formation [4] and psychiatric processes [5],
and is involved in central feeding control [6].
PACAP is also known to be expressed in the retina, along
with its receptors (PAC1, VPAC1, and VPAC2 receptors).
Numerous studies have provided evidence that the neuro-
protective effects are mainly mediated by the PAC1 receptor
and diverging downstream pathways upon its activation [7–
9]. The PAC1 receptor has several splice variants, which can
mediate not only different but also opposing effects [10].
Several research groups have proven that PACAP has strong
protective effects against various retinal injuries. In vitro, it
protects retinal explants against excitotoxic injury [11] and
retinal pigment epithelial cells against oxidative stress [12]. In
vivo retina studies show that PACAPprotects againstNMDA-
and MSG-induced excitotoxic damage [13, 14], UV light-
induced lesion [15], and optic nerve lesion [16]. Recent studies
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show that PACAP is also protective in diabetic retinopathy
[17]. Retinal ischemia can be induced by several methods,
mimicking pathological features seen in human glaucoma-
related retinal lesions, in chronic retinal hypoperfusion, and
in other types of retinal lesions accompanied by ischemia.
The protective role of PACAP has also been proven inmodels
of retinal ischemia [18, 19]. Based on these studies, evidence
for the protective effects of PACAP in the retina is now well
established [20].
The bioavailability and fast degradation of PACAP limit
its therapeutic use and attention has been drawn to the appli-
cation of shorter fragments and/or analogs. N-terminally
shorter fragments of PACAPusually have antagonistic effects,
but some reports have documented agonistic behavior,
depending on the cell/tissue type [7–9, 21, 22]. In contrast,
C-terminally shorter fragments usually differ in the strength
of receptorial binding [7–9]. Therefore, it is necessary to test
whether shorter PACAP fragments have any effect, amelio-
rating or damaging, on retinal lesions. We have previously
shown that PACAP 6-38, the most widely used antagonist
of PACAP, has an aggravating effect on retinal excitotoxic
lesion [23]. However, it is not known, whether the shorter
fragments of PACAP have any effect on the retina.Therefore,
the first aim of our present study was to examine the effects
of PACAP fragments 4-13, 4-22, 6-10, 6-15, 11-15, and 20-31
on chronic retinal hypoperfusion induced by bilateral carotid
artery occlusion. Possible fragments to be testedwere selected
in order to cover a wide range of the molecule, from the N-
terminal to the C-terminal and middle region of the peptide.
In addition, the N-terminal fragments show a high similarity
with the structure of VIP. Furthermore, the 4-13 domain,
for example, shows high selectivity to the PAC1 receptor,
which is mainly responsible for the neuroprotective effects
of PACAP [7–9]. In a recent study we have shown that the
peptide most closely related to PACAP, namely, vasoactive
intestinal peptide (VIP), is also protective in retinal ischemia.
However, to achieve a degree of neuroprotection similar to
PACAP, higher doses are required [24]. Other members of
the peptide family have not been tested in retinal ischemia
so far. Therefore, the second aim of the present study was to
investigate whether secretin and glucagon have any effect on
a rat model of retinal ischemia.
2. Materials and Methods
Experimental animals were derived from a local colony of
Wistar rats. Animals were housed in individual cages, fed,
and watered ad libitum, under light/dark cycles of 12/12 h.
All animal procedures complied with the University of
Pecs (number BA02/2000-15024/2011) for the ethical use of
animals. Adult male rats (𝑛 = 32) weighing 250–300 g
were exposed to permanent bilateral common carotid artery
occlusion (BCCAO) under isoflurane anesthesia and both
common carotid arteries were ligated with a 3-0 filament
through a midline incision [19]. A group of animals under-
went anesthesia and all steps of the surgical procedure,
except ligation of the carotid arteries. These animals served
as sham-operated animals (𝑛 = 7). Immediately following
the operation, PACAP 1-38 or its fragments (PACAP 4-13,
4-22, 6-10, 6-15, 11-15, and 20-31) or other members of the
peptide family such as secretin and glucagon (100 pmol/5 𝜇L)
were injected intravitreally using 30-gauge Hamilton syringe
into the right vitreous body of animals. The left eyes received
the same volumes of vehicle treatment (physiological saline)
and served as ischemic eyes. Rats were sacrificed with an
overdose of anesthetic after 2 weeks of BCCAO and the eyes
were processed for histological analysis. Briefly, the eyes were
dissected in PBS and fixed in 4% paraformaldehyde dissolved
in 0.1M PB. Following fixation, tissues were embedded in
DurcupanACM resin, cut at 2𝜇m, and stained with toluidine
blue. Four tissue blocks from at least four animals were
prepared and central retinal areas within 1mm from the optic
nerve were used for measurements (𝑛 = 5 measurements
from one tissue block). Photographs were taken with a digital
CCD camera using the Spot program. Sections where the
GCL appeared thicker than a single cell row were omitted
from evaluation. The following parameters were measured:
(i) the width of the outer and inner nuclear and plexiform
layers (ONL, OPL, INL, and IPL, resp.); (ii) the number of
cells/100 𝜇m section length in the ganglion cell layer (GCL);
(iii) the number of cells/500 𝜇m2 area in the INL. Results
are presented as mean± SEM. Statistical comparisons were
made using the ANOVA test followed by Tukey-B’s post hoc
analysis.
3. Results and Discussion
BCCAO resulted in severely reduced thickness of retinal
layers as observed two weeks after ligation compared to
sham-operated controls (Figure 1(a)). Marks of degeneration
with individual variations are visible in all retinal layers
(Figure 1(b)). Morphometric analysis revealed that the most
pronounced reduction in thickness in retinas with BCCAO
was found in the OPL (Figure 2). The photoreceptor layer
was also reduced in thickness (Figure 1(b)). This layer was
significantly thinner than that of the control specimens
(Figure 2). Many cells in the ganglion cell layer (GCL) also
suffered degeneration, shown by necrotic cells in this layer
(Figures 1 and 2). This fact is well reflected in the reduced
number of cells in the GCL (Figure 2). Intraocular PACAP
1-38 treatment following BCCAO led to nearly healthy
appearance of the retinal layers (Figure 1(c)). This is also
well supported by the morphometric measurements. The
thickness of the major retinal layers was almost identical
with that of the sham-operated animals and was significantly
larger than that of control ischemic ones (Figure 2). This was
especially conspicuous in the OPL, which disappeared, and
theONL and INL layers were fused in several control animals
and were preserved in all PACAP 1-38 injected animals.
However, the number of cells in the GCL seemed to be
lower than in the sham-operated animals (Figure 2). Indeed,
some degenerating cells could be discerned in the GCL in
these preparations. This may have led to a decrease in cell
numbers.
Intravitreal injection of different PACAP fragments
(PACAP 4-22, 6-15, 11-15, 20-31, 6-10, and 4-13) did not
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Figure 1: Representative light microphotographs of retinal sections. Retinal tissue from SHAM-operated animal (a) compared to BCCAO
retinas (b). Representative sections from retinas treated with PACAP 1-38 (c) and PACAP fragments: PACAP 4-22 (d), 6-15 (e), 11-15 (f),
20-31 (g), 6-10 (h), and 4-13 (i). In contrast to PACAP 1-38 (c), the PACAP fragments (d–f) did not ameliorate the BCCAO-induced retinal
degeneration. On the contrary, treatment with some fragments led to a more pronounced degeneration, which was shown by the width of
the retinal layers and the neural profiles in the ONL and INL. ONL: outer nuclear layer; OPL: outer plexiform layer; INL: inner nuclear layer;
IPL: inner plexiform layer; GCL: ganglion cell layer (scale bar: 20𝜇m).
(a) (b)
Figure 2:Morphometric analysis of retinal layers (a) and number of cells/100 𝜇mGCL length and number of cells/500 𝜇m2 INL (b) in SHAM
operated animals, with BCCAO and with BCCAO+different PACAP fragments. We did not detect retinoprotective effects after the injection
of the PACAP fragments (PACAP 4-22, 6-15, 11-15, 20-31, 6-10, and 4-13). ONL: outer nuclear layer; OPL: outer plexiform layer; INL: inner
nuclear layer; IPL: inner plexiform layer; GCL: ganglion cell layer. ∗𝑃 < 0.05 compared to SHAM retinas; #𝑃 < 0.05 compared to BCCAO
retinas.
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Figure 3: Light microphotographs of retinal sections (toluidine blue). Representative retinas from BCCAO+ secretin (a) and
BCCAO+ glucagon (b). The whole retina structure (especially ONL and INL) was damaged by BCCAO compared to SHAM retinas. The
PACAP related peptide secretin (a) and glucagon (b) did not ameliorate the ischemic degeneration (scale bar: 20𝜇m).
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Figure 4: Morphometric analysis of retinal layers (a) and number of cells/100 𝜇m GCL length and number of cells/500 𝜇m2 INL (b) in
secretin- and glucagon-treated retinas. The retinoprotective effects of secretin or glucagon were not quantified by the thickness (𝜇m) of
retinal layers (a) OPL, INL, and IPL and number of cells/100𝜇m GCL length or the number of cells/500 𝜇m2 in the INL (b). ONL: outer
nuclear layer; OPL: outer plexiform layer; INL: inner nuclear layer; IPL: inner plexiform layer. ∗𝑃 < 0.05 compared to SHAM retinas.
ameliorate the ischemic damage of the retina (Figures 1(d)–
1(i)). In all samples, nuclear layers (ONL, INL) and plexiform
layers (OPL, IPL) were reduced, and the cell number in the
GCL was significantly less than in sham-operated controls.
However, injection with PACAP 6-10 and 4-13 resulted in
further reduction of the inner plexiform and nuclear layers
(Figures 1(h) and 1(i)). Treatment with members of the
PACAP-related peptide superfamily, glucagon and secretin,
led to no aggravation or amelioration of the ischemic retinal
lesion (Figure 3). These observations were confirmed by
morphometric measurements (Figure 4).
PACAP is a member of the secretin/glucagon/VIP super-
family of peptides. PACAP and its receptors occur in the
retina [25]. PACAP is thought to play an important role
in visual processing, as it is an important cotransmitter
in the retinohypothalamic tract that is the major input
for the biological clock situated in the suprachiasmatic
nucleus [26]. Besides its supposed physiological actions in the
retina, PACAP is a well-established retinoprotective peptide.
Endogenous protection is proven by the increased vulnera-
bility of the retina in mice lacking endogenous PACAP in
ischemic retinal lesion [2] and inNMDA-induced excitotoxic
injury [14]. These observations are further supported by the
increased apoptotic activity in retinas injected by the PACAP
antagonist PACAP 6-38 [27]. As PACAP is a well-accepted
retinoprotective agent in models of different retinal injuries,
several studies have attempted to explore the molecular
mechanisms explaining this strong retinoprotection [27].
We have shown that PACAP activates the antiapoptotic,
while it inhibits the proapoptotic signaling pathways in
retinal toxic lesions [27]. In retinal ischemia, we have shown
that PACAP administration provides protection by involv-
ing Akt, MAPK pathways, and anti-inflammatory actions
[28].
Given the very potent actions of PACAP in retinal and
other pathologies, there is an urging demand for devel-
oping novel analogues and/or fragments to increase the
bioavailability and stability of the peptide for future potential
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therapeutic use [7, 8]. Binding PACAP to other carrier
molecules is a possibility to increase its capacity to traverse
through membranes and to exert cytoprotective effects [29].
It has also been shown that PACAP is able to pass through cell
membranes and convey nonreceptor mediated effects [30].
This has raised the possibility of using PACAP fragments also
for supporting transport of other nonpenetrable molecules
[31]. Several analogues have also been developed for these
purposes [7, 8, 32]. Interestingly, however, a stable analogue
did not provide stronger neuroprotection in a stroke model
than the natural peptide [33]. Unfortunately, all these efforts
do not seem to lead to obtaining of a more effective molecule
than the original peptide or to obtaining of a biologically
more stable analogue that has the same protective property
as PACAP 1-38. The evolutionary pressure on the form of
PACAP 1-38 seems to be very strong, as effects found in verte-
brates have also been described in invertebrates [7]. Although
a lot of pharmacological and receptor binding studies have
been performed with fragments/analogues of PACAP, only
few studies have tested the biological efficacy of these forms
[33]. Since some studies suggest that there are unconventional
binding sites, unusual behavior of the peptide forms in some
tissues and even implies the existence of unknown receptor
splice variants [21, 22, 34]; it is important to test the biological
effects of fragments in a system that is well standardized in
numerous earlier studies. Our present results show that the
shorter fragments of PACAP, as expected, do not provide any
neuroprotection. In addition, we can confirm that most of
themdonot deteriorate the degree of damage either, although
some parameters were worsened in cases of PACAP 6-10
and 4-13. This is in accordance with our earlier observations
showing that PACAP antagonists PACAP 6-38 and 6-27 lead
to aggravated retinal lesion in anMSG-induced retinal injury
model [23].
Relatively little is known about other members of the
peptide family in the retina. Some other members of this
family have been localized in the vertebrate retina and several
functions have been attributed to them [35, 36]. Glucagoner-
gic amacrine cells represent a small subpopulation of the
amacrine cells possibly playing a role in the visual processing
[37, 38]. Other studies have shown that glucagon plays a role
in eye bulb growth and glucagon is suggested to be an endoge-
nous mediator of emmetropization [39]. An early study has
shown that glucagon increases cAMP in chick retinal Muller
cells, similar to the actions of VIP [40]. The protective effects
of secretin and glucagon in cerebral pathologies have been
implicated in a few studies [41–43]. In cerebral ischemia,
glucagon has been shown to exert neuroprotective effects in
vivo [41]. It has not been investigated so far whether secretin
or glucagon is protective in retinal lesions. Based on our
present study, neither glucagon nor secretin has protective
action in retinal ischemia. Based on our present and previous
results, a strong neuroprotective effect is a specific PACAP-
action, since VIP could exert its protective effects only in
much higher doses, while secretin and glucagon did not have
any effects.
Our present results confirm that the natural form of the
peptide, PACAP 1-38, is the most effective peptide form in
retinal ischemia, and the 38 amino acid form of the peptide
cannot be replaced by another fragment or another member
of the peptide family that we know of. Our results further
support the potent retinoprotective effects of PACAP and call
for further studies to establish the future possible clinical
introduction of PACAP-related retinoprotective therapeutic
approach.
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